778277-15-9

Basic information

• Product Name: GNF5
• Synonyms: GNF 5;GNF5;GNF-5;N-(2-Hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzamide;ert-butyl 2-oxopiperidine-1-carboxylate;GNF 5 N-(2-Hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzamide;N-(2-Hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzamide GNF-5;GNF-5, >=98%
• CAS NO: 778277-15-9
• Molecular Formula: C₂₀H₁₇F₃N₄O₃
• Molecular Weight: 418.3691896
• EINECS: 200-256-5
• Product Categories: Inhibitors
• Mol File: 778277-15-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 612.4±55.0 °C(Predicted)
• Appearance: white to beige/
• Density: 1.385±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble10mg/mL (clear solution)
• PKA: 13.36±0.46(Predicted)
• CAS DataBase Reference: GNF5(CAS DataBase Reference)
• NIST Chemistry Reference: GNF5(778277-15-9)
• EPA Substance Registry System: GNF5(778277-15-9)

Safety Data

• Hazard Codes: T
• Statements: 25-36
• Safety Statements: 22-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 778277-15-9(Hazardous Substances Data)

Usage

General Description

GNF5 is a small molecule chemical compound that belongs to the GNF family of inhibitors. It is a potent and selective inhibitor of glycogen synthase kinase 3 (GSK-3) and has been shown to exhibit anti-cancer activity by impairing cancer cell growth and inducing apoptosis. GNF5 has also been implicated in the regulation of Wnt/β-catenin signaling pathway, which plays a critical role in cell proliferation and differentiation. Due to its promising anti-cancer properties, GNF5 has been investigated as a potential therapeutic agent for the treatment of various types of cancers, including breast, lung, and colon cancer, and holds potential for further development as a targeted therapy for cancer patients.

Upstream product

• 714962-05-7 3-(6-((4-(trifluoromethoxy)phenyl)amino)pyrimidin-4-yl)benzoic acid 
• 141-43-5 ethanolamine 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR TREATING CANCERS

This invention provides a combination of ATP-competitive BCR-ABL inhibitor and a non-ATP competitive BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with BCR-ABL.